Search

Your search keyword '"Jeremy Rudnick"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Jeremy Rudnick" Remove constraint Author: "Jeremy Rudnick"
56 results on '"Jeremy Rudnick"'

Search Results

1. Clinical response to pazopanib in a patient with endolymphatic sac tumor not associated with von Hippel-Lindau syndrome

2. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.

3. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas

4. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma

5. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma

6. INNV-12. A SINGLE-INSTITUTION RETROSPECTIVE REVIEW OF PATIENTS WITH CNS TUMORS WHO INITIATED A KETOGENIC DIET

7. Profiles of brain metastases: Prioritization of therapeutic targets

8. QOLP-20. DIETARY, ACTIVITY, AND QUALITY OF LIFE METRICS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA IMPLEMENTING A KETOGENIC DIET: RESULTS OF A PHASE 1 CLINICAL TRIAL

9. CTIM-05. A PHASE 1/2 STUDY OF THE COMBINATION OF INDOXIMOD AND TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY HIGH-GRADE GLIOMAS

10. QOLP-04. THE KETOGENIC DIET PLUS STANDARD CARE FOR RECENTLY DIAGNOSED GLIOBLASTOMA: A PHASE 1 SAFETY AND FEASIBILITY TRIAL

11. SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas

12. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk

13. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

14. RARE-17. LENALIDOMIDE AS TREATMENT FOR RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTIONAL EXPERIENCE

15. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies

16. Corrigendum to 'Clinical Practice Experience With Novo TTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)'

17. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS

18. ACTR-15. PHASE 1 TRIAL OF A KETOGENIC DIET IN PATIENTS RECEIVING STANDARD-OF-CARE TREATMENT FOR RECENTLY DIAGNOSED GLIOBLASTOMA

19. OS2.5 Long term remission/survival over 8 years in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 dendritic cell-based immunotherapy (phase I)

20. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21. Atypical and anaplastic meningiomas treated with bevacizumab

22. ATIM-18. A PHASE I TRIAL OF VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE DERIVED FROM AN ALLOGENEIC GLIOBLASTOMA STEMLIKE CELL LINE FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA

23. Adult Brainstem Glioblastoma Multiforme: Long-term Survivor

24. IMPS-35UNUSUAL TUMOR INFILTRATING LYMPHOCYTES IN DE NOVO GLIOBLASTOMA FOLLOWING PRE-TREATMENT WITH ANTI-PD-L1 THERAPY FOR PRECEDING METASTATIC NSCLC: CASE PRESENTATION WITH DISCUSSION

25. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

26. Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy

27. RM-02LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS FOLLOWING STROKE: A NON-CONSECUTIVE CASE SERIES

28. ED-38AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

29. IT-13IPILIMUMAB FOR RECURRENT HIGH-GRADE GLIOMA: A SINGLE-INSTITUTION CASE SERIES

30. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe)

31. NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data

32. The homeodomain-containing gene Xdbx inhibits neuronal differentiation in the developing embryo

33. NEURO/MEDICAL ONCOLOGY

34. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article

35. ATIM-25. TEN-YEAR FOLLOW UP WITH LONG TERM REMISSION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ICT-107 VACCINE (PHASE I)

36. IMCT-12A PHASE 1 TRIAL OF VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE DERIVED FROM AN ALLOGENEIC GLIOBLASTOMA STEM-LIKE CELL LINE FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA

37. The Impact of Temozolomide on Post Radiation Therapy Progression Free Survival in Low Grade Glioma

38. BM-09 * USE OF NEUROENDOSCOPY TO SAFELY DELIVER INTRATHECAL CHEMOTHERAPY AT THE TIME OF OMMAYA RESERVOIR PLACEMENT

39. Abstract 2692: Nanoconjugates for inhibition of laminin-411-integrin β1-Dll4-Notch1 pathway to treat glioblastoma multiforme

40. Alternating Electric Fields Therapy for Recurrent Glioblastoma - Novottf-100A System: Updated Outcomes and Toxicity Based on the Analysis of Patient Registry Data

41. P17.95 * NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

42. Ipilimumab for recurrent glioblastoma: A single-institution case series

43. Does Early Radiosurgery to Residual Enhancement Improve Outcome following Subtotal Resection of GBM?

44. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation

45. Retrospective analysis of glioblastoma patients treated with bevacizumab who presented with multifocal disease at diagnosis

46. Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine

47. The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma

48. Prognostic significance of new glioma marker, laminin-411, and its inhibition by targeted nanobiopolymer in vivo

49. Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma

50. Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)

Catalog

Books, media, physical & digital resources